With $1M seed, Kinnos wants to make bleach better

Ronny Kerr · March 8, 2017 · Short URL: https://vator.tv/n/4914

In new interview, Brooklyn-based healthtech company talks about the business of decontamination

Editor's note: Our Splash Health, Wellness and Wearables event is coming up on March 23 in San Francisco. We'll have Mario Schlosser (Founder & CEO of Oscar Health), Brian Singerman (Partner, Founders Fund), Steve Jurvetson (Draper Fisher Jurvetson), J. Craig Venter (Human Longevity), Lynne Chou (Partner, Kleiner Perkins), Michael Dixon (Sequoia Capital), Patrick Chung (Xfund), Check out the full lineup and register for tickets before they jump! If you want to invest as little as $2500 in our startup winners. Join the Vator Investment Club (VIC).


Who knew that bleach could be improved?

Kinnos just closed a $1 million seed round led by Georgica Advisors, with participation from New York Angels, VentureWell, and other strategic angel investors.

The Brooklyn-based company developed its first product, Highlight, in response to the Ebola crisis in West Africa. Because disinfectants like bleach are transparent, it can be difficult to see where they have been applied. It's easy to miss a spot, and that can make a life or death difference when dealing with highly contagious diseases.

In the below interview, we hear from Kinnos CEO Jason Kang about the problem his company set out to solve, ongoing use cases, as well as the broader healthtech industry. Take a listen:

Stay tuned to learn more.

Support VatorNews by Donating

Read more from our "The Ronny Kerr Show" series

More episodes

Related Companies, Investors, and Entrepreneurs

Kinnos Inc.


Joined Vator on

Kinnos is a New York-based healthcare company that aims to raise the standard of infectious disease decontamination. Our first product, Highlight, is a patent-pending additive for disinfectants that greatly improves visibility, coverage, and end-user compliance. Highlight is used by the Fire Department of New York, was a grantee of the USAID Fighting Ebola Grand Challenge, and has been field-tested in Liberia, Guinea, and Haiti. Kinnos has been recognized as winners of the Lemelson-MIT Student Prize, Collegiate Inventors Competition, and Columbia Venture Competition, and has been featured in the Wall Street Journal, Scientific American, and as Forbes 30 Under 30 in Healthcare.


Jason Kang

Joined Vator on